The estimated Net Worth of Brendan P.Eckelman Living T... is at least $39.8 Milione dollars as of 1 March 2023. Brendan T owns over 40,000 units of Inhibrx stock worth over $30,533,295 and over the last 4 years Brendan sold INBX stock worth over $9,232,856.
Sign up
Brendan T INBX stock SEC Form 4 insiders trading
Brendan has made over 12 trades of the Inhibrx stock since 2021, according to the Form 4 filled with the SEC. Most recently Brendan sold 40,000 units of INBX stock worth $968,400 on 1 March 2023.
The largest trade Brendan's ever made was selling 40,000 units of Inhibrx stock on 1 March 2023 worth over $968,400. On average, Brendan trades about 28,171 units every 53 days since 2021. As of 1 March 2023 Brendan still owns at least 2,035,553 units of Inhibrx stock.
You can see the complete history of Brendan T stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Inhibrx
Over the last 4 years, insiders at Inhibrx have traded over $27,711,393 worth of Inhibrx stock and bought 2,717,119 units worth $64,845,764 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management, L.P.Kol... e Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of $1,598,400. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth $671,000.
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
What does Inhibrx's logo look like?
Complete history of Brendan T stock trades at Inhibrx
Inhibrx executives and stock owners
Inhibrx executives and other stock owners filed with the SEC include:
-
Mark Paul Lappe,
Founder, Chairman, Pres & CEO -
Dr. Klaus W. Wagner,
Chief Medical Officer & Exec. VP -
Dr. Brendan P. Eckelman Ph.D.,
Founder, Chief Scientific Officer & Exec. VP of Corp. Strategy -
Kelly Devine Deck B.S., CPA, M.S.,
Chief Financial Officer -
Klaus Wagner,
Executive Vice President, Chief Medical Officer -
Kelly Deck,
Chief Financial Officer -
Quinn Deveraux,
Co-Founder, Executive Vice President - Early Research -
Brendan Eckelman,
Co-Founder, Executive Vice President - Corporate Strategy, Chief Scientific Officer -
Mark Lappe,
Chairman of the Board, Chief Executive Officer, Founder -
David Matly M.B.A.,
Exec. VP & Chief Commercial Officer -
Jeffrey J. Jensen,
Exec. VP of Clinical Operations -
Leah Pollema J.D.,
VP, Corp. Sec. & Gen. Counsel -
Dr. Ashraf Amanullah,
Exec. VP & Chief Technical Operations Officer -
Capital Management, L.P.Kol...,
-
Brendan P. Eckelman,
Chief Scientific Officer -
Jon Faiz Kayyem,
Director -
Global Investors Lp Viking ...,
-
Kristiina Md Vuori,
Director -
Douglas Forsyth,
Director -
Kimberly Manhard,
Director -
Global Investors Lp Viking ...,
-
Inc. Inhibrx,,
-
Mark Lappe,
Chief Executive Officer